Novartis provides safety update for Beovu

A safety review into Novartis’ new anti-VEGF drug Beovu has revealed that reported adverse events are consistent with the approved prescribing information after a group of US retinal specialists linked it to a series of vasculitis cases. Read more

Optometrists move to urgent care model amid COVID-19

Optometrists across Australia, including the country’s largest optical chains and independent groups, have adapted their service models in response to the COVID-19 emergency and are hopeful of restoring normality to their businesses within a month. Read more